Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

The American Journal of Surgical Pathology, published by Lippincott Williams & Wilkins, is a premier peer-reviewed journal serving as a vital resource for pathologists, surgeons, and researchers in the medical field. With an impressive impact factor reflective of its esteemed standing in the academic community, the journal ranks in the Q1 quartile for Anatomy, Pathology and Forensic Medicine, and Surgery as of 2023. The journal's Scopus rankings further highlight its significance, placing it within the top tiers in multiple medical disciplines. Established in 1977 and continuing through 2024, its scope encompasses groundbreaking research, critical reviews, and updates in surgical pathology, making it an essential tool for advancing the scientific community's understanding of disease mechanisms and therapeutic approaches. Researchers, clinicians, and students will find both comprehensive studies and innovative insights, ensuring they remain informed about the latest developments in surgical pathology.

PATHOLOGY INTERNATIONAL, published by WILEY, stands as a distinguished journal in the field of pathology and forensic medicine, serving as an essential resource for researchers, clinicians, and students alike. With its ISSN 1320-5463 and E-ISSN 1440-1827, PATHOLOGY INTERNATIONAL has established itself since its inception in 1951, navigating through an evolving landscape in medical science with insights and breakthroughs up to 2024. It holds a commendable Q2 ranking in both the Medicine (miscellaneous) and Pathology and Forensic Medicine categories, indicating its robust influence and quality within these fields, as evidenced by its placement in the 70th percentile of Scopus rankings. While currently not an open-access journal, it provides access options that ensure valuable research remains available to the academic community. PATHOLOGY INTERNATIONAL commits to advancing the discipline through pioneering research articles, comprehensive reviews, and expert opinions that push the boundaries of understanding in pathology, thereby supporting the enhancement of diagnostic and therapeutic practices.

MODERN PATHOLOGY is a premier journal in the field of pathology and forensic medicine, published by Elsevier Science Inc. With an impressive impact factor that places it in the top 1st quartile (Q1) for 2023, and a remarkable rank of 5 out of 208 in its category according to Scopus, it serves as a vital resource for researchers, professionals, and students alike. Established in 1988, the journal focuses on the latest advancements in diagnostic pathology, molecular pathology, and related fields, providing a platform for innovative research that drives the discipline forward. Although it does not operate under an open access model, readers can expect rigorously peer-reviewed publications that contribute to the growing body of knowledge in pathology. With a continuous commitment to excellence and relevance, MODERN PATHOLOGY remains a fundamental avenue for disseminating high-quality scientific research globally, facilitating the growth and development of its field.

NEOPLASMA is a prominent journal published by AEPRESS SRO, dedicated to the multifaceted field of oncology and cancer research. Since its inception in 1957, this esteemed publication has served as a vital platform for advancing the understanding of neoplastic diseases, disseminating high-quality research findings that contribute to clinical and laboratory advancements. Operating under a robust framework of peer review, NEOPLASMA holds significant credibility, as evidenced by its Q2 ranking in the Medicine (miscellaneous) category and Q3 rankings in both Cancer Research and Oncology for 2023. Furthermore, with an ISSN of 0028-2685 and E-ISSN 1338-4317, the journal fosters accessibility to valuable scientific content despite the absence of open access options. Positioned in Bratislava, Slovakia, NEOPLASMA continues to attract a global readership, making substantial contributions to the fields of biochemistry, genetics, and molecular biology as highlighted by its Scopus rankings. This journal is essential reading for researchers, professionals, and students looking to stay abreast of the latest developments in cancer research and treatment strategies.

MOLECULAR CARCINOGENESIS is a prestigious academic journal published by Wiley, dedicated to advancing the understanding of the molecular basis of cancer. Established in 1988, this journal serves as a vital resource for researchers and professionals in the fields of cancer research and molecular biology. With an impressive impact factor reflecting its significance in the Q2 category for both Cancer Research and Molecular Biology, it stands out for its high-quality, peer-reviewed articles that explore innovative research, novel findings, and emerging trends in carcinogenesis. Although the journal currently does not offer open access options, it remains accessible to the academic community through numerous institutional subscriptions. Positioned in the United States and contributing to the global discourse on cancer research, MOLECULAR CARCINOGENESIS is an essential publication for anyone engaged in the study of cancer at the molecular level.

The Journal of Pathology and Translational Medicine, published by the Korean Society of Pathologists, is a distinguished peer-reviewed Open Access journal that has been at the forefront of advancing the field of pathology and histology since its inception in 1985. With an established ISSN of 2383-7837 and an E-ISSN of 2383-7845, the journal serves as a vital platform for disseminating high-quality research, fostering collaboration among professionals and offering valuable insights into both clinical applications and theoretical advancements. Recognized for its influence in the field, it holds a commendable Q2 ranking in both Histology and Pathology & Forensic Medicine categories in 2023, and ranks #52/208 in Scopus for Medicine – Pathology and Forensic Medicine, demonstrating its impact and reach within the academic community. Located in South Korea at 1209 Gwanghwamun Officia, 92 Saemunan-ro, Jongno-gu, Seoul 03186, this journal not only caters to researchers and professionals but also supports students striving to deepen their understanding of pathology. Join the growing body of knowledge and stay updated with the latest findings in this essential field of study through the journal's open access format, promoting worldwide accessibility and engagement.

ENDOCRINE PATHOLOGY is a premier journal published by HUMANA PRESS INC, dedicated to advancing the understanding of endocrine disorders through innovative research and clinical practices. With an impressive impact factor and consistently ranked in the Q1 quartile across multiple categories such as Endocrinology, Diabetes and Metabolism, as well as Pathology and Forensic Medicine, this journal serves as a pivotal resource for researchers and professionals in the field. The journal covers a broad spectrum of topics related to endocrine pathology, providing insights into mechanisms, diagnostics, and therapeutics that inform both clinical and laboratory practices. Although it does not offer open access, its rigorous peer-review process ensures the dissemination of high-quality, impactful research that shapes clinical strategies and enhances patient care. With distribution spanning from its inception in 1990 to 2024, ENDOCRINE PATHOLOGY stands at the forefront of endocrine research, making it an essential read for anyone involved in the study and treatment of endocrine disorders.

Veterinary and Comparative Oncology is a leading academic journal published by WILEY, providing a vital platform for the dissemination of groundbreaking research in the field of veterinary oncology. With an impressive impact factor and ranked as Q1 in the Veterinary (Miscellaneous) category for 2023, the journal is recognized for its quality and influence, placing it in the top 10% of its field. Covering a wide array of topics, from the pathogenesis of tumors in animals to innovative treatment strategies, it aims to enhance the understanding of cancer biology and therapy in veterinary medicine. The journal has an E-ISSN of 1476-5829, with its scope expanding from 2007 to 2024, reflecting an ongoing commitment to the advancement of veterinary science. Located in the United Kingdom, its global reach facilitates the exchange of knowledge among researchers, professionals, and students. For those interested in significant and impactful studies, Veterinary and Comparative Oncology remains an essential resource in the ever-evolving landscape of veterinary medicine.

BMC CANCER is a prestigious, peer-reviewed journal dedicated to advancing the field of cancer research and oncology since its inception in 2001. Published by BMC, a leading name in open-access publishing, this journal plays a crucial role in providing researchers, professionals, and students with a platform for high-quality scientific discourse. With an impressive impact factor, BMC CANCER is ranked in the Q2 quartile across multiple categories, including Cancer Research, Genetics, and Oncology, reflecting its commitment to impactful research and rigorous peer-review standards. The journal ensures broad accessibility to its content through its Open Access model, allowing findings to reach a global audience without financial barriers. The editorial board consists of recognized experts committed to fostering innovation and collaboration within the cancer research community. Researchers working at the intersection of cancer biology, treatment options, and genetic influences will find BMC CANCER an invaluable resource for sharing their findings and engaging with the latest developments in the field.